KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables RefundsShares OutstandingShares Repurchased
Ratios

Royalty Pharma (RPRX) EBIAT (2019 - 2025)

Historic EBIAT for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $355.9 million.

  • Royalty Pharma's EBIAT rose 644.89% to $355.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year decrease of 116.97%. This contributed to the annual value of $1.3 billion for FY2025, which is 49.75% down from last year.
  • Per Royalty Pharma's latest filing, its EBIAT stood at $355.9 million for Q4 2025, which was up 644.89% from $444.2 million recorded in Q3 2025.
  • Over the past 5 years, Royalty Pharma's EBIAT peaked at $806.8 million during Q2 2021, and registered a low of -$610.0 million during Q4 2022.
  • In the last 5 years, Royalty Pharma's EBIAT had a median value of $278.1 million in 2021 and averaged $291.8 million.
  • As far as peak fluctuations go, Royalty Pharma's EBIAT crashed by 123661.01% in 2022, and later soared by 897143.16% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's EBIAT stood at $53.7 million in 2021, then tumbled by 1236.61% to -$610.0 million in 2022, then surged by 217.63% to $717.6 million in 2023, then plummeted by 53.41% to $334.4 million in 2024, then grew by 6.45% to $355.9 million in 2025.
  • Its last three reported values are $355.9 million in Q4 2025, $444.2 million for Q3 2025, and $90.6 million during Q2 2025.